Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock

In the latest episode of Mad Money, on September 8, financial commentator Jim Cramer highlighted pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) as a fantasy defense stock for his portfolio. Cramer explained that while fantasy football defenses aim to minimize points conceded, they can also generate upside through sacks, turnovers, and special teams touchdowns.

Similarly, Merck serves as a defensive stock in the market, performing well even during economic downturns and potentially benefiting from significant upside gains. The company's stocks surged by 41% year to date, mirroring the performance of the Los Angeles Rams defense in the NFL. The primary concern for Merck is the racing clock to develop new drugs to counteract patent expirations for its key oncology platform, Keytruda.

Strong commercial assets, such as Keytruda and the subcutaneous Keytruda QLEX, have generated $8.4 billion in quarterly revenue. Management has raised full-year 2026 sales guidance to $66.3 billion to $67.3 billion. However, Merck must focus on accelerating its pipeline with partnerships like its collaboration with Moderna on personalized mRNA cancer vaccines, despite the risk of clinical, regulatory, manufacturing, and commercialization challenges.

Hedge fund data reveals that 101 funds held Merck stock in Q2, with Fisher Asset Management leading the pack by increasing its holdings by 46%. The low short interest of just 0.99% of the float indicates that market skeptics see little reason to bet against Merck's success. With consistent dividend distributions, steady pharmaceutical revenue, and potential for long-term clinical upside, Merck appears to be a reliable stock for balanced equity portfolios.